CPIC 2026 | 中日健康产业合作专场

安斯泰来制药全球业务开发负责人

Global Head of Business Development, Astellas Pharma

全面负责安斯泰来制药从风险投资、研发合作、许可到并购等各项合作事务。加入安斯泰来前，他曾于武田药品工业株式会社担任日本业务开发负责人，主导了包括Shire收购后日本产品组合转型在内的多项重大业务开发交易。此外，他还拥有11年的药物发现研发经验，具备从早期研究到商业化的全链条视野。基于上述丰富的行业经验，在本次CPIC2026日中合作论坛上，Tsukamoto博士将作为安斯泰来的业务开发最高负责人，就公司的战略优先领域、所需技术及资产、合作形式（如引进许可、共同研发、并购等）进行演讲，并通过专题推介会（pitch session），招募通过日中企业间合作与联盟共同创造事业发展的合作伙伴。

Fully responsible for all partnership activities at Astellas Pharma, ranging from venture investment, R&D collaboration, licensing to mergers and acquisitions. Prior to joining Astellas, he served as Head of Japan Business Development at Takeda Pharmaceutical Company, where he led multiple major business development transactions, including the transformation of Japan's product portfolio following the acquisition of Shire. Furthermore, he possesses 11 years of drug discovery and R&D experience, providing a comprehensive perspective spanning from early-stage research to commercialization.

Based on this extensive industry experience, at the CPIC2026 Japan-China Cooperation Forum, Dr. Tsukamoto will speak as Astellas' highest-ranking business development executive on the company's strategic priority areas, required technologies and assets, and partnership models (such as in-licensing, co-development, and M&A). Through a dedicated pitch session, he will recruit partners for collaborative business development through Japan-China corporate cooperation and alliances.

川本BioBusiness Partners合伙人代表 / 上海大邦律师事务所（上海）高级顾问

Representative, Kawamoto BioBusiness Partners / Senior Advisor, Shanghai Deband Law Firm (Shanghai)

中日跨境创新药业务拓展与合作伙伴关系谈判专家。其职业生涯始于藤泽药品（现安斯泰来制药），25年间通过许可合作、合资以及在美国三年的派驻，推动了国际业务的发展。2005年他在日本创立了川本BioBusiness&IP事务所，专注于知识产权战略、商业模式构建、代表日企跟欧美药企合同谈判。他还曾担任三家公司的外部董事。

2012年移居上海后，与中日企业合作，协助达成跨境创新药合作协议。近期与中方共同建立“中日生物医药合作快通路”平台，促进中日企业合作与跨境联盟。作为推动日本企业参与CPIC2026的促进者，他将担任2026年日中合作论坛的日方组织者，致力于深化相互理解并推进创新药领域的合作伙伴关系。

An expert in cross-border innovative drug business development and partnership negotiations between China and Japan. He began his career at Fujisawa Pharma (now Astellas Pharma), where 25 years he advanced international business through licensing, joint ventures, and a three-year assignment in the United States. In 2005, he founded Kawamoto BioBusiness & IP Firm in Japan, focusing on IP strategy, business model structuring, and contract negotiation representing Japanese companies in deals with Western pharmaceutical firms. He also served as an outside director for three companies.

Since relocating to Shanghai in 2012, he has collaborated with Chinese and Japanese companies to facilitate cross-border innovative drug partnership arrangements. Recently, together with Chinese partners, he established the “Japan-China BioPharma Fast-Track Cooperation Platform” to promote collaboration and cross-border alliances between Japanese and Chinese companies. As a promoter of Japanese participation in CPIC2026, he will serve as the Japanese organizer of the 2026 Japan-China Cooperation Forum, dedicated to deepening mutual understanding and advancing partnerships in the innovative drug sector.

大会特设10000㎡专业展厅，用于企业/机构品牌展示与交流洽谈。